Elevance Health (NYSE:ELV) Releases FY 2025 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 30.000-30.000 for the period, compared to the consensus estimate of 29.920. The company issued revenue guidance of -.

Analyst Ratings Changes

ELV has been the topic of several analyst reports. TD Cowen lifted their price target on Elevance Health from $330.00 to $380.00 and gave the stock a “buy” rating in a report on Thursday. Bank of America lifted their price target on Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, October 10th. Leerink Partnrs lowered shares of Elevance Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Morgan Stanley boosted their price objective on shares of Elevance Health from $316.00 to $359.00 and gave the company an “equal weight” rating in a report on Tuesday, October 14th. Finally, Argus restated a “hold” rating on shares of Elevance Health in a report on Monday, July 21st. Twelve equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $397.89.

Elevance Health Stock Performance

NYSE ELV opened at $342.45 on Friday. The stock has a 50-day moving average of $327.09 and a two-hundred day moving average of $353.39. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.56 and a quick ratio of 1.44. The company has a market cap of $76.11 billion, a P/E ratio of 14.00, a P/E/G ratio of 1.26 and a beta of 0.59. Elevance Health has a 1-year low of $273.71 and a 1-year high of $458.75.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.03 by $1.00. The firm had revenue of $50.09 billion during the quarter, compared to the consensus estimate of $49.26 billion. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the company posted $8.37 earnings per share. As a group, analysts anticipate that Elevance Health will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 19th. Investors of record on Friday, December 5th will be issued a $1.71 dividend. This represents a $6.84 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Friday, December 5th. Elevance Health’s dividend payout ratio is 27.96%.

Insiders Place Their Bets

In other news, Director Susan D. Devore acquired 1,200 shares of Elevance Health stock in a transaction on Tuesday, August 19th. The stock was bought at an average price of $312.15 per share, for a total transaction of $374,580.00. Following the completion of the purchase, the director owned 3,502 shares in the company, valued at $1,093,149.30. This represents a 52.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.29% of the company’s stock.

Institutional Investors Weigh In On Elevance Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC lifted its stake in Elevance Health by 68.3% in the second quarter. Advisory Services Network LLC now owns 3,833 shares of the company’s stock valued at $1,491,000 after buying an additional 1,556 shares during the last quarter. State of Wyoming purchased a new stake in Elevance Health in the second quarter valued at approximately $127,000. Kestra Investment Management LLC lifted its stake in Elevance Health by 20.8% in the second quarter. Kestra Investment Management LLC now owns 709 shares of the company’s stock valued at $276,000 after buying an additional 122 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in Elevance Health by 4.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 288,545 shares of the company’s stock valued at $112,403,000 after buying an additional 12,520 shares during the last quarter. Finally, MUFG Securities EMEA plc purchased a new stake in shares of Elevance Health during the second quarter worth approximately $260,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.